Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLCBusiness Wire • 05/19/21
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CMLBusiness Wire • 05/19/21
Takeda Pharmaceutical Company Limited's (TAK) CEO Christophe Weber on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Takeda says it may double imports of Moderna shots to help accelerate Japan vaccinationReuters • 05/11/21
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021Business Wire • 05/11/21
Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category Awards for 2021 Facilities of the YearBusiness Wire • 04/28/21
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung CancerBusiness Wire • 04/27/21
Coursera, Lattice Semiconductors, Qualcomm and More Monday Afternoon Analyst Calls24/7 Wall Street • 04/19/21
Takeda: Why Now Is The Time For Taking The Opportunity For Getting On The Takeda A-TrainSeeking Alpha • 04/01/21
Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to BlackstoneBusiness Wire • 03/31/21
Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic CountriesBusiness Wire • 03/25/21
Anima Attracts Takeda In Multibillion-Dollar mRNA Translation Modulators Deal For Neurological DiseasesBenzinga • 03/18/21
IDT Biologika To Make J&J's COVID-19 Vaccine Using Takeda's Manufacturing CapacityBenzinga • 03/15/21
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)Business Wire • 03/15/21